Spyryx Biosciences, which recently initiated a Phase 2 study of its SPX-101 inhaled SPLUNC1-derived peptide for the treatment of cystic fibrosis, announced that former United Therapeutics CEO Roger Jeffs has joined its board of directors.
Jeffs served as President and COO of United Therapeutics from 1998-2014 and as President and CEO from January 2015 until mid 2016. He currently serves on the boards of Albireo Pharma, Axsome Therapeutics, Dova Pharmaceuticals and Sangamo Therapeutics.
Spyryx President and CEO John Taylor commented, “I’m excited to have Roger join our board and to have the opportunity to work with him to advance Spyryx’s product and corporate development efforts. He has a successful track record, particularly in rare pulmonary diseases, and I know his insights and experience will be a major positive for Spyryx as we move SPX-101 through Phase 2 for cystic fibrosis, as well as investigate the opportunity for our compounds in additional indications.”
Jeffs said, “I am thrilled to join the Spyryx Board at such an exciting time in the company’s life cycle. The board and management team have done an excellent job of advancing this important therapeutic class into the clinic and developing broad IP with large commercial potential across a number of underserved indications.”
Read the Spyryx Biosciences press release.
